Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19

Sponsor
Universidade do Porto (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05054075
Collaborator
Instituto Politécnico de Bragança (Other)
45
2
3
13
22.5
1.7

Study Details

Study Description

Brief Summary

The present work proposes to find if a bio-active composite in the hemolymph or plasma of the freshwater bivalve Anodonta cygnea is able to offer immunity and specificity for meliorating the major symptoms in human SARS and COVID-19 lineage infection. The Methodology concerns in silico procedures using organic fluids from 54 bivalves (in very specific conditions) to evaluate their therapeutic effects in 6 voluntary SARS and COVID-19 infected persons with an integrative diagnosis by a computational Mora®Nova apparatus to access the basal and experimental human physiological parameters.

Condition or Disease Intervention/Treatment Phase
  • Biological: Marine liquid and fluids
  • Biological: Impregnation
  • Biological: Incubation
  • Biological: Manipulation
  • Biological: Refrigeration
Phase 2

Detailed Description

A deep and consistent study will be developed with an increase in the human sampling for better understanding the intervention efficacy of this intelligence medicine integrator, the Mora® Nova method. These in silico experiments when associated with the bioresonance frequencies from stimulated hemolymph compounds of the freshwater bivalve A. cygnea, may lead us to expect high plasticity and immunological potential.

Obviously, additional in vitro studies in future, with adequate culture cell lineages in different conditions and with bioresonance treatment by Mora® Nova method, should also be accomplished with hemolymph/plasma interference to confirm the pertinence, and the real efficacy on SARS / COVID-19 infection as well as to clarify the respective biological mechanisms.

In addition, to analyze and evaluate any specific bioactive compound from the induced hemolymph condition needs molecular experiments which can give deep structural information concerning any efficient molecule against the SARS / COVID-19 virus lineage and respective mutants. Effectively, according to current scientific opinion, the virus mutation phenomenon leads to great and problematic difficulty for maintaining the collective and human global immunization. In this case, the present Mora methodology offers a very functional, dynamic, and efficient process when combined with a biological model, as the bivalve A. cygnea, with high plasticity and eventual molecular reconstructive adaptation. This Mora procedure can extend to other immune-depressive diseases namely cancer, rheumatoid arthritis, and neurodegenerative diseases combining with respective stimulated bivalve fluids. It suggests opening a promising future perspective when applied to large human sampling as well as with in vitro cellular assays.

In addition, to explore this research with in vitro cell cultures and to do the characterization and the effects from bio-compounds on similar diseases is our close objective.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
45 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Methodological Design for Evaluating the Immune Capacity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 Human Infection: Intelligent Medicine Integration.
Actual Study Start Date :
Oct 1, 2021
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Vaccinated

Subjects that received a vaccine against COVID-19 lineage virus

Biological: Marine liquid and fluids
Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)

Biological: Impregnation
SARS / COVID-19 fluid/liquid - impregnation

Biological: Incubation
SARS / COVID-19 fluid-bivalve-incubation

Biological: Manipulation
Bivalve Manipulation - Stress inducing

Biological: Refrigeration
Refrigerated fluid to check for maintained response

Experimental: Non-vaccinated

Subjects that did not receive a vaccine against COVID-19 lineage virus

Biological: Marine liquid and fluids
Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)

Biological: Impregnation
SARS / COVID-19 fluid/liquid - impregnation

Biological: Incubation
SARS / COVID-19 fluid-bivalve-incubation

Biological: Manipulation
Bivalve Manipulation - Stress inducing

Biological: Refrigeration
Refrigerated fluid to check for maintained response

Experimental: Infected

Subjects that are infected with a COVID-19 lineage virus

Biological: Marine liquid and fluids
Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)

Biological: Impregnation
SARS / COVID-19 fluid/liquid - impregnation

Biological: Incubation
SARS / COVID-19 fluid-bivalve-incubation

Biological: Manipulation
Bivalve Manipulation - Stress inducing

Biological: Refrigeration
Refrigerated fluid to check for maintained response

Outcome Measures

Primary Outcome Measures

  1. Pulmonary system [T0 - Day 1 - Baseline]

    Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints

  2. Pulmonary system change [T1 - Day 1 - After in silico human virus infestation]

    Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints

  3. Pulmonary system change [T2 - Day 1 - After adding the interface of the original fluid]

    Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints

  4. Pulmonary system change [T3 - Day 1 - After adding the interface of virus impregnated fluid]

    Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints

  5. Pulmonary system change [T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours]

    Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints

  6. Cardiac system [T0 - Day 1 - Baseline]

    Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints

  7. Cardiac system change [T1 - Day 1 - After in silico human virus infestation]

    Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints

  8. Cardiac system change [T2 - Day 1 - After adding the interface of the original fluid]

    Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints

  9. Cardiac system change [T3 - Day 1 - After adding the interface of virus impregnated fluid]

    Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints

  10. Cardiac system change [T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours]

    Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints

  11. Immunologic system [T0 - Day 1 - Baseline]

    Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints

  12. Immunologic system change [T1 - Day 1 - After in silico human virus infestation]

    Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints

  13. Immunologic system change [T2 - Day 1 - After adding the interface of the original fluid]

    Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints

  14. Immunologic system change [T3 - Day 1 - After adding the interface of virus impregnated fluid]

    Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints

  15. Immunologic system change [T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours]

    Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints

Secondary Outcome Measures

  1. Gastrointestinal system [T0 - Day 1 - Baseline]

    Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints

  2. Gastrointestinal system Change [T1 - Day 1 - After in silico human virus infestation]

    Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints

  3. Gastrointestinal system Change [T2 - Day 1 - After adding the interface of the original fluid]

    Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints

  4. Gastrointestinal system Change [T3 - Day 1 - After adding the interface of virus impregnated fluid]

    Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints

  5. Gastrointestinal system Change [T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours]

    Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints

  6. Nervous system [T0 - Day 1 - Baseline]

    Voll Electromagnetic conductance reading (Hz) on nervous system biopoints

  7. Nervous system change [T1 - Day 1 - After in silico human virus infestation]

    Voll Electromagnetic conductance reading (Hz) on nervous system biopoints

  8. Nervous system change [T2 - Day 1 - After adding the interface of the original fluid]

    Voll Electromagnetic conductance reading (Hz) on nervous system biopoints

  9. Nervous system change [T3 - Day 1 - After adding the interface of virus impregnated fluid]

    Voll Electromagnetic conductance reading (Hz) on nervous system biopoints

  10. Nervous system change [T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours]

    Voll Electromagnetic conductance reading (Hz) on nervous system biopoints

  11. Endocrine system [T0 - Day 1 - Baseline]

    Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints

  12. Endocrine system change [T1 - Day 1 - After in silico human virus infestation]

    Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints

  13. Endocrine system change [T2 - Day 1 - After adding the interface of the original fluid]

    Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints

  14. Endocrine system change [T3 - Day 1 - After adding the interface of virus impregnated fluid]

    Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints

  15. Endocrine system change [T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours]

    Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints

Eligibility Criteria

Criteria

Ages Eligible for Study:
14 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects with normal physiological state or any kind of comorbidity
Exclusion Criteria:
  • Subjects in highly critical health state

Contacts and Locations

Locations

Site City State Country Postal Code
1 Instituto Politécnico de Bragança Bragança Portugal
2 ICBAS - University of Porto Porto Portugal 4050-313

Sponsors and Collaborators

  • Universidade do Porto
  • Instituto Politécnico de Bragança

Investigators

  • Study Director: Jorge P Machado, PhD, ICBAS - Instituto de Ciências Biomédicas Abel Salazar

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jorge Pereira Machado, Principal Investigator, Universidade do Porto
ClinicalTrials.gov Identifier:
NCT05054075
Other Study ID Numbers:
  • BivalveSarsCov-Protocol
  • PPA nº 117380
First Posted:
Sep 23, 2021
Last Update Posted:
Apr 15, 2022
Last Verified:
Apr 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 15, 2022